Welcome to our dedicated page for WATERS /DE/ SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WATERS /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WATERS /DE/'s regulatory disclosures and financial reporting.
Waters Corp director Linda Baddour reported receiving new equity awards. On February 25, 2026, she acquired stock options for 57 shares of common stock at an exercise price of $0.00 per share and 23 shares of common stock granted at no cost.
All 57 option shares and the 23 restricted common shares vest on February 9, 2027. Following these grants, she directly holds 2,899 shares of common stock and 57 stock options in Waters Corp.
Ornskov Flemming reported acquisition or exercise transactions in this Form 4 filing.
Waters Corp director Flemming Ornskov reported equity awards, not open-market trades. On February 25, 2026, he received a grant of 336 shares of common stock at no cash cost, increasing his directly held common shares to 5,271.
He also received a stock option for 57 shares at no cash cost. According to the footnotes, the 336-share award is subject to restrictions that lapse on February 9, 2027, and all 57 option shares will vest and become exercisable on February 9, 2027.
Waters Corporation filed its annual report describing a major expansion and evolving risk profile. The company remains a global leader in liquid chromatography, mass spectrometry and thermal analysis, serving pharmaceutical, industrial, academic and government customers, with 59% of 2025 net sales from pharmaceutical accounts and 69% of sales generated outside the U.S.
The centerpiece is the $16.8 billion acquisition of BD’s Biosciences and Diagnostic Solutions businesses, structured as a Reverse Morris Trust. BD shareholders now own about 39.2% of the combined company and Waters shareholders 60.8%. Management projects approximately $200 million in cost synergies within three years and $290 million in revenue synergies within five years, alongside restructuring of manufacturing, supply chain and commercial infrastructure.
Waters assumed $4.0 billion of new debt through SpinCo, on top of $1.4 billion outstanding as of December 31, 2025, and plans to refinance a $3.5 billion tranche in early 2026. The report highlights integration challenges, higher leverage, restrictions under a Tax Matters Agreement, macroeconomic and China-related demand risks, competitive pressures, product quality and AI-related risks, but underscores continued investment in R&D, new instruments and software, and a broad, diversified customer base.
Waters Corp director Claire Fraser reported her initial ownership of 131 shares of Waters common stock, held directly. According to the disclosure, 128 of these shares were received on February 9, 2026 in exchange for 953 shares of Augusta SpinCo common stock immediately before her appointment to the board. The remaining 3 shares were already held by her at that time. The spin-related transactions included a distribution of one Augusta SpinCo share for each Becton, Dickinson and Company share held as of the close of business on February 5, 2026, followed by an exchange of each SpinCo share for approximately 0.135343148384084 Waters common shares.
Waters Corporation completed its previously announced Reverse Morris Trust transaction combining Becton, Dickinson’s Biosciences and Diagnostic Solutions business with Waters. BD shareholders received 38,541,851 shares of Waters common stock and now hold about 39.2% of the combined company on a fully diluted basis, while former Waters shareholders hold about 60.8%.
The BD carve-out business (SpinCo) paid BD $4.0 billion in cash funded by a new $4.0 billion unsecured term loan facility, split between a $3.5 billion 364‑day tranche and a $500 million two‑year tranche, guaranteed by Waters and key subsidiaries. For the year ended September 30, 2025, the acquired BDS Business generated $3,296 million in revenue and $353 million in net income.
Waters also expanded its board from 10 to 11 members and appointed genome scientist Claire M. Fraser, Ph.D., who will receive standard non‑employee director cash and equity compensation, including an initial equity grant valued at $229,166.
Waters Corporation reported solid fourth quarter and full-year 2025 results and issued strong 2026 guidance alongside closing its acquisition of BD Biosciences and Diagnostic Solutions. Fourth quarter 2025 sales were $932 million, up 7%, with non-GAAP EPS up 10% to $4.53, while GAAP diluted EPS slipped slightly to $3.77.
For full-year 2025, sales grew 7% to $3.17 billion, GAAP EPS was $10.76 versus $10.71, and non-GAAP EPS rose 11% to $13.13. Growth was led by pharmaceutical and industrial markets and by recurring service and chemistry revenues. Cash and cash equivalents increased to $587.8 million, and debt declined to $1.41 billion.
For 2026, Waters expects total reported revenue of $6.41–$6.46 billion including about $3.0 billion from the acquired BD businesses and revenue synergies, with organic reported revenue of $3.36–$3.41 billion. Full-year 2026 non-GAAP EPS is guided to $14.30–$14.50, implying roughly 8.9–10.4% growth, while GAAP EPS is projected at $6.63–$6.83 due to acquisition-related charges.
Waters Corporation senior vice president Robert L. Carpio III reported a small insider transaction involving company common stock. On February 5, 2026, 38 shares were withheld by Waters to cover tax obligations tied to the vesting of previously reported restricted stock units at $376.89 per share. After this tax withholding, Carpio beneficially owns 2,618 shares of Waters common stock directly.
Waters Corporation senior vice president Jianqing Bennett reported equity compensation activity involving company common stock. On February 4, 2026, Bennett acquired 1,385 shares at $0 per share upon certification of performance-based restricted stock units that were originally granted on February 8, 2023, and tied to service and performance conditions.
The units convert into common stock on a one-to-one basis upon vesting and settlement, with full vesting scheduled upon satisfaction of the service-based requirement on March 1, 2026. On February 5, 2026, 43 shares at $376.89 per share were withheld by Waters to cover tax obligations related to previously reported restricted stock unit vesting, leaving Bennett with 6,258 directly held shares.
Waters Corp SVP & CFO Amol Chaubal reported equity compensation activity. On February 4, 2026, he acquired 1,884 shares of common stock at $0 following the vesting of previously granted performance-based restricted stock units, increasing his direct holdings to 7,108.393 shares.
On February 5, 2026, 58 shares at $376.89 were withheld by Waters to cover tax obligations tied to earlier restricted stock unit vesting, leaving Chaubal with 7,050.393 directly owned shares. The performance-based units were originally granted on February 8, 2023 and are scheduled to vest in full on March 1, 2026, converting to common stock on a one-to-one basis upon vesting and settlement.
Waters Corporation President and CEO Udit Batra reported equity award activity involving company common stock. On February 4, 2026, he acquired 7,066 shares at $0 upon certification of performance-based restricted stock units granted in 2023. These PSUs convert one-for-one into common shares when vesting conditions are met.
On February 5, 2026, 218 shares of common stock were withheld at $376.89 per share to cover tax obligations tied to vesting of previously reported restricted stock units. Following these transactions, Batra directly owned 31,392 shares of Waters common stock.